Condition: Crohn Disease · Sponsor: Eli Lilly and Company
The main purpose of this study is to see how the safety and efficacy of a farnesoid X receptor (FXR) agonist (LY4395089), given together with mirikizumab compares with mirikizumab (alone) in adults with moderately to severely active Crohn's disease (CD). This study is part of the IIBD master protocol and will last approximately 62 weeks.
This description comes directly from the study's public registry record.
There may be multiple sites in this clinical trial. (Add "This 1-877-CTLILLY (1-877-285-4559) or · 1-317-615-4559 · clinical_inquiry_hub@lilly.com
Always discuss trial participation with your own doctor first.
| Mayo Clinic in Arizona - Scottsdale | Scottsdale, Arizona, United States | Not Yet Recruiting |
| Biopharma Informatic, LLC | Los Angeles, California, United States | Not Yet Recruiting |
| Om Research LLC | Oxnard, California, United States | Recruiting |
| South Denver Gastroenterology | Englewood, Colorado, United States | Recruiting |
| Gastro Health Research - Miami | Miami, Florida, United States | Not Yet Recruiting |
| Ezy Medical Research | Miami Lakes, Florida, United States | Recruiting |
| Atlanta Gastroenterology Associates - Peachtree Dunwoody | Atlanta, Georgia, United States | Recruiting |
| Rush University Medical Center | Chicago, Illinois, United States | Not Yet Recruiting |
| Cotton O'Neil Digestive Health Center | Topeka, Kansas, United States | Recruiting |
| Gastroenterology Associates of Western Michigan, PLC d.b.a. West Michigan Clinical Research Center | Wyoming, Michigan, United States | Not Yet Recruiting |
| KAD Clinical Research | St Louis, Missouri, United States | Not Yet Recruiting |
| Vector Clinical Trials | Las Vegas, Nevada, United States | Recruiting |
+ 59 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07483099